Clovis Oncology to discontinue mid-stage bladder cancer trial
However, Clovis Oncology said it would continue to test the drug, Rubraca, in combination with other treatments for bladder cancer.
New Delhi: Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 per cent.
The company said its decision to discontinue the trial was based on recommendations of an independent committee, which suggested that the treatment may not provide a meaningful benefit to patients.
Also Read: JnJ gets USFDA nod to Balversa for treating bladder cancer
However, Clovis said it would continue to test the drug, Rubraca, in combination with other treatments for bladder cancer.
The drug is also being tested in late-stage trials as a treatment for ovarian cancer as well as for treating patients with prostate cancer.
Rubraca belongs to a new class of cancer drugs called PARP-inhibitors, which work by blocking enzymes involved in repairing damaged DNA of cancer cells, thereby helping to kill them.
Also Read: Astrazeneca, Merck wins EU nod for Lynparza to treat breast cancer
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd